Navigation Links
Taxus VI Clinical Trial Demonstrates Positive Long-Term Outcomes,for Moderate-Release Paclitaxel-Eluting Stent at Four Years

ntrolled study of 446 patients at 44 international sites is designed to assess the TAXUS moderate-release paclitaxel-eluting coronary stent system in reducing restenosis in high-risk patients, including de novo lesions with overlapping stents, lesions 26 mm or greater in length and small vessels. Lesion size ranged from 18 - 40 mm in length and 2.5 - 3.75 mm in diameter. TAXUS VI is the first randomized, controlled clinical trial to demonstrate durability of drug-eluting stents in complex lesions at four years. Follow-up included 98 percent of the patients enrolled at four years.

The study's results demonstrate a continued significant reduction in target lesion revascularization (TLR, or retreatment rate) as compared to the bare-metal stent control group at four years. The four-year TLR rate was 12.9 percent for the TAXUS Stent group, as compared with 21.4 percent for the control group (P=0.0082 (only two TLR events were reported between three and four years for the TAXUS Stent group)). The rate of patients living free of TLR events was 87.1 percent at four years for the TAXUS Stent group, as compared to 78.6 percent for the bare-metal stent control group.

The four-year results for TAXUS VI support long-term safety with the increased levels of paclitaxel in the moderate-release formulation used in the study. Even with an in vitro dosing rate 8-10 times greater than the commercialized slow-release formulation, no compromise in safety was observed. The TAXUS Stent group continues to report no new stent thrombosis after two years with a low 2.4 percent cardiac death rate.

Boston Scientific launched the slow-release formulation TAXUS Express2 paclitaxel-eluting coronary stent system in Europe and other international markets in 2003 and in the United States in 2004. The Company launched the slow-release formulation TAXUS(R) Liberte(TM) paclitaxel-eluting coronary stent system in Europe and other international markets in 2005. The TAXUS Express modera
'"/>




Page: 1 2 3

Related medicine technology :

1. New Study Suggests Better Patient Outcomes with CYPHER Sirolimus-Eluting Coronary Stent than with Taxus Stent in Real-World Clinical Settings
2. Positive Results for Second-Generation Taxus Liberte Coronary Stent System Highlighted in Journal of American College of Cardiology
3. SPIRIT Clinical Data Reaffirm Strength of Taxus and Promus Drug-Eluting Coronary Stent Systems
4. Abbotts Xience V Everolimus Eluting Coronary Stent Superior to Taxus Stent in Spirit III U.S. Pivotal Clinical Trial
5. Genetic Analysis Systems Enter the Clinical Mainstream
6. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
7. Large Geographic Differences in EpiPen Prescriptions in the U.S., From the Journal of Allergy and Clinical Immunology
8. Clinical Data Suggest Decreased Bleeding Risk in People With Severe Hemophilia A While Maintaining Factor VIII Levels Above One Percent
9. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
10. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
11. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
Post Your Comments:
(Date:11/21/2014)... Calif. and VIENNA, Va. ... innovative in-home care provider that operates in ... a leading provider of remote caregiving technology. Alta will ... and existing client receiving homecare services. Logo ... this technology is the key to providing the kind ...
(Date:11/21/2014)... Fla. , Nov. 21, 2014   Rock ... announced that the Company is scheduled to present at ... San Francisco, CA on January 12-14, 2015. ... Chairman and CEO of Rock Creek Pharmaceuticals, will present ... molecule cholinergic agonist which exhibits anti-inflammatory pharmacological characteristics. Dr. ...
(Date:11/21/2014)... , Nov. 21, 2014  Abaxis, Inc. (NasdaqGS: ... instruments and consumables for the medical, research, and veterinary ... veterinary and research markets in the United ... stock purchase agreement to acquire 100% of QCR & ... based distribution organization. The transaction closed on November ...
Breaking Medicine Technology:Alta Home Care, Inc. and BeClose Partner to Enable Seniors to Remain in Their Homes Safely and Securely 2Rock Creek Pharmaceuticals to Present at the Biotech Showcase 2015 2Rock Creek Pharmaceuticals to Present at the Biotech Showcase 2015 3Rock Creek Pharmaceuticals to Present at the Biotech Showcase 2015 4Abaxis Acquires UK-based Distribution Organization 2Abaxis Acquires UK-based Distribution Organization 3Abaxis Acquires UK-based Distribution Organization 4
... 16, 2007 - Amgen,(Nasdaq:AMGN) today presented the results ... the,efficacy and safety of Aranesp(R) (darbepoetin alfa) for ... not receiving,chemotherapy or radiotherapy ("the 103 study"). Aranesp ... EMEA in these patients. These,results were presented in ...
... WIRE)--Apr 16, 2007 - Arsenic, a naturally,occurring element, ... years, and even now remains a venerable constituent ... to the efforts of investigators supported,by grants from ... Walls," an arsenic derivative is being,utilized in therapy ...
Cached Medicine Technology:Aranesp Phase 3 Study in Patients with Active Cancer Not Receiving,Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual,Meeting 2Aranesp Phase 3 Study in Patients with Active Cancer Not Receiving,Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual,Meeting 3Aranesp Phase 3 Study in Patients with Active Cancer Not Receiving,Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual,Meeting 4Aranesp Phase 3 Study in Patients with Active Cancer Not Receiving,Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual,Meeting 5Aranesp Phase 3 Study in Patients with Active Cancer Not Receiving,Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual,Meeting 6Aranesp Phase 3 Study in Patients with Active Cancer Not Receiving,Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual,Meeting 7Research Supported by Samuel Waxman Cancer Research Foundation,Discovers Mode of Action of Arsenic-Based Drugs in Destroying,Cancer Cells 2Research Supported by Samuel Waxman Cancer Research Foundation,Discovers Mode of Action of Arsenic-Based Drugs in Destroying,Cancer Cells 3
(Date:11/24/2014)... November 24, 2014 Volpara Solutions ... 1.2 at the 100th Annual Meeting of the ... 5, 2014 (RSNA Booth 1752 – South Hall). ... VolparaAnalytics and the rest of its innovative suite ... VolparaDoseRT, which enable personalized measurements of volumetric density, ...
(Date:11/24/2014)... Recently, SweetDressy.com, a well-known dress supplier and leader ... 2014 Evening Dresses. All these fresh items are offered ... manager, the special offer is valid until Dec. 20, ... has been working well in the fashion industry for ... Their new dresses may be the best products for ...
(Date:11/24/2014)... SafeHandles™ announced that they will be featured in ... airing via Discovery Channel. Dates and show times TBA. ... replaceable, and affordable germ protective device. This segment will ... adhesives to promote hand hygiene in high traffic and ... is the desire to make a positive impact in ...
(Date:11/23/2014)... The clinical trial report, "Aspergillosis Global ... the Aspergillosis clinical trial scenario. This report provides ... trials on Aspergillosis. It includes an overview of ... per the site of trial conduction across the ... disease clinical trials by their phase, trial status, ...
(Date:11/23/2014)... November 23, 2014 Pro Ace Care, a ... it will now be providing an 8 year warranty on ... water tank installations went up due to the impending winter ... its customers of the premium service that the company provides. ... year warranty on John Wood and Bradford hot water tanks. ...
Breaking Medicine News(10 mins):Health News:Volpara Solutions to Launch VolparaAnalytics 1.2 at RSNA 2Health News:Volpara Solutions to Launch VolparaAnalytics 1.2 at RSNA 3Health News:SweetDressy.com Unveiled A New Selection Of Evening Dresses 2Health News:New Episode of Innovations TV Series to Feature SafeHandles™ 2Health News:Aspergillosis Pipeline and Clinical Trials Market (Compnies and Drugs) Review H2 2014 Report at ReportsnReports.com 2Health News:Aspergillosis Pipeline and Clinical Trials Market (Compnies and Drugs) Review H2 2014 Report at ReportsnReports.com 3Health News:Aspergillosis Pipeline and Clinical Trials Market (Compnies and Drugs) Review H2 2014 Report at ReportsnReports.com 4Health News:Pro Ace Care Now Gives 8 Year Guarantee on Selected Vancouver Hot Water Tanks 2
... popularity of weight training has grown over the past ... Injury Research and Policy of The Research Institute at ... injuries from weight training has increased as well. The ... were treated in U.S. hospital emergency departments between 1990 ...
... ... independent inspections and audits that enable AIB’s worldwide foodservice clients to lower business ... ... North America,s largest providers of third-party food safety audits , recently selected ...
... comment on risks from scans , TUESDAY, March 30 (HealthDay ... much radiation will get a public airing this week as ... meetings on what should be done to increase the safety ... seeking ideas to get manufacturers of the devices used for ...
... ... Can Benefit From A Posture Brace ( www.posturenow.com ) , ... (PRWEB) March 30, 2010 -- Within minutes ... the blogosphere was abuzz with comments about Chad Ochocinco’s poor posture. , , ,Chad’s ...
... ... Approach to Application Whitelisting by Verifying Insecure Software and Applications to Help Customers Improve ... ... Lumension , a global leader in endpoint management and security, today announced it has ...
... ... elder care law, released this statement concerning a March/April AARP article entitled "Love is (Not) ... for 44 years was forced to divorce in order to protect their remaining savings to ... off the mark , ...
Cached Medicine News:Health News:New national study examines weight training-related injuries 2Health News:New national study examines weight training-related injuries 3Health News:AIB International to Implement MetricStream for Compliance and Safety Audits 2Health News:AIB International to Implement MetricStream for Compliance and Safety Audits 3Health News:AIB International to Implement MetricStream for Compliance and Safety Audits 4Health News:Too Much Radiation? The FDA Wants to Know 2Health News:Too Much Radiation? The FDA Wants to Know 3Health News:Dancing With The Slouching Stars: Chad Ochocinco Fumbles When It Comes To Posture 2Health News:Lumension Partners With Citrix To Advance Desktop Virtualization Security 2Health News:Lumension Partners With Citrix To Advance Desktop Virtualization Security 3Health News:Lumension Partners With Citrix To Advance Desktop Virtualization Security 4Health News:Lumension Partners With Citrix To Advance Desktop Virtualization Security 5Health News:Prominent National Elder Law Attorney Disputes AARP Article Recommending Divorce to Afford Health Care 2Health News:Prominent National Elder Law Attorney Disputes AARP Article Recommending Divorce to Afford Health Care 3
... Volu-Sol's New Methylene Blue, ... to use. This stain ... does not require any counter-staining. ... in three different sizes, 30 ...
... in methanol for faster, more complete ... smears. Our special manufacturing process yields ... elements producing unequaled definition of cytoplasmic ... brilliance in the resulting smear. Used ...
... Volu-Sol's Stat Stain is ideal for stat, ... stain blood smears (10-15 seconds) and bone ... generates finely dispersed stain particles which yield ... eliminates many of the steps involved in ...
... single-solution staining, Hema-Quik II for ... into stain solution for five ... deionized water for five to ... time by dipping quickly in ...
Medicine Products: